JOP20210281A1 - بروتينات سكرية محمضة بالسَّيَاليك - Google Patents

بروتينات سكرية محمضة بالسَّيَاليك

Info

Publication number
JOP20210281A1
JOP20210281A1 JOP/2021/0281A JOP20210281A JOP20210281A1 JO P20210281 A1 JOP20210281 A1 JO P20210281A1 JO P20210281 A JOP20210281 A JO P20210281A JO P20210281 A1 JOP20210281 A1 JO P20210281A1
Authority
JO
Jordan
Prior art keywords
shear stress
stable
sialylated glycoproteins
pharmaceutical
preparations
Prior art date
Application number
JOP/2021/0281A
Other languages
English (en)
Inventor
Siddhesh D Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20210281A1 publication Critical patent/JOP20210281A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

يصف الاختراع المستحضرات الصيدلانية المحتوية على جلوبولينات مناعية مفرطة التحميض بالسياليك. وتكون تلك المستحضرات مستقرة لإجهاد القص. توفر التركيبات الصيدلانية الموصوفة هنا تركيبات hsIgG المقبولة صيدلانيًا والتي تكون مستقرة ضد إجهاد القص (على سبيل المثال، لا يتشكل عدد كبير من الجسيمات غير المرئية عندما تتعرض التركيبة إلى إجهاد القص، مثل التحريض، على سبيل المثال، أثناء الشحن) وبالتالي يمكن شحنها ومعالجتها في شكل سائل.
JOP/2021/0281A 2019-04-18 2020-04-17 بروتينات سكرية محمضة بالسَّيَاليك JOP20210281A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
JOP20210281A1 true JOP20210281A1 (ar) 2023-01-30

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0281A JOP20210281A1 (ar) 2019-04-18 2020-04-17 بروتينات سكرية محمضة بالسَّيَاليك

Country Status (20)

Country Link
US (1) US20220211849A1 (ar)
EP (1) EP3955962A4 (ar)
JP (1) JP2022529168A (ar)
KR (1) KR20220002963A (ar)
CN (1) CN113795275A (ar)
AU (1) AU2020259492A1 (ar)
BR (1) BR112021020509A8 (ar)
CA (1) CA3137101A1 (ar)
CL (1) CL2021002668A1 (ar)
CO (1) CO2021013926A2 (ar)
CR (1) CR20210521A (ar)
EA (1) EA202192860A1 (ar)
EC (1) ECSP21078309A (ar)
IL (1) IL287306A (ar)
JO (1) JOP20210281A1 (ar)
MX (1) MX2021012710A (ar)
PE (1) PE20220383A1 (ar)
SG (1) SG11202110942SA (ar)
WO (1) WO2020215021A1 (ar)
ZA (1) ZA202109184B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
US20230417762A1 (en) 2020-11-20 2023-12-28 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832756A (zh) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0614100A2 (pt) * 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
EP2435474A2 (en) * 2009-05-27 2012-04-04 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
WO2014052360A2 (en) * 2012-09-26 2014-04-03 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
WO2014179601A2 (en) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN105324487B (zh) * 2013-05-29 2020-01-17 豪夫迈·罗氏有限公司 唾液酸化的定量控制
JP7177777B2 (ja) * 2017-01-11 2022-11-24 セルトリオン， インク． 安定した液体製剤

Also Published As

Publication number Publication date
US20220211849A1 (en) 2022-07-07
WO2020215021A1 (en) 2020-10-22
SG11202110942SA (en) 2021-11-29
BR112021020509A8 (pt) 2023-01-10
EP3955962A1 (en) 2022-02-23
BR112021020509A2 (pt) 2022-03-15
ZA202109184B (en) 2023-04-26
CO2021013926A2 (es) 2021-10-29
MX2021012710A (es) 2021-11-12
CL2021002668A1 (es) 2022-05-27
PE20220383A1 (es) 2022-03-18
IL287306A (en) 2021-12-01
JP2022529168A (ja) 2022-06-17
EP3955962A4 (en) 2022-12-14
ECSP21078309A (es) 2021-11-30
CA3137101A1 (en) 2020-10-22
CN113795275A (zh) 2021-12-14
AU2020259492A1 (en) 2021-11-11
EA202192860A1 (ru) 2021-12-23
KR20220002963A (ko) 2022-01-07
CR20210521A (es) 2022-04-01

Similar Documents

Publication Publication Date Title
JOP20210281A1 (ar) بروتينات سكرية محمضة بالسَّيَاليك
MX2017012878A (es) Composiciones gomosas de multicomponentes con nucleo duro.
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
US20130012601A1 (en) Fluid Cocamide Monoethanolamide Concentrates And Methods Of Preparation
WO2017037075A8 (de) Zusammensetzung enthaltend einen extrakt aus echinacea und linolsäurederivate
MX2022014216A (es) Nueva composicion farmaceutica para administracion de farmacos.
MX2023014446A (es) Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
BR112015019580A2 (pt) processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica
WO2019031898A3 (ko) 약학 조성물 및 이의 제조방법
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2022006130A (es) Composiciones inyectables de ácido ursodeoxicólico.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
BR112017019753A2 (pt) uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
PH12020551547A1 (en) Pharmaceutical preparation
MX2022005317A (es) Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
MX2017013265A (es) Composicion para formulacion cosmetica humectante de larga duracion que comprende manteca de ucuuba con altas concentraciones de acido miristico asi como el uso de la formulacion para la preparacion de un producto cosmetico altamente humectante y kit.
MX2019000846A (es) Preparaciones de vitaminas que contienen galato de propilo.
KR101779676B1 (ko) 균일한 혼합도의 투석액 조제용 조성물의 제조방법
MX2022006601A (es) Composicion espesante de alimento y metodo.
MX2020010928A (es) Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
MX2022005044A (es) Formulacion de anticuerpo que contiene crizanlizumab.